8.34
price up icon17.11%   1.21
after-market After Hours: 8.36 0.02 +0.24%
loading

Why is Canopy Growth Corporation (CGC) Stock down?

We've noticed a 7.30% decline in Canopy Growth Corporation (CGC) stock during the 2024-06-25 trading session. While this could be attributed to normal volatility or various internal and external factors, please be aware that we are actively monitoring the situation, and we'll provide timely updates as soon as possible!
09 Apr, 2024:

Canopy Growth Corporation (CGC) stock fell by 9.49% following the bad news from canabis company Tilray Brands (TLRY),which reported a miss on sales and a $0.12 per share net loss.

  • Tilray's Performance and Industry Implications: Tilray's reported growth numbers were mixed, with 30% total sales growth but some disappointment in the marijuana sales growth, which investors were hoping for more from. Much of Tilray's marijuana sales growth came from its acquisition of Hexo, indicating that organic growth in the marijuana industry may be slower than anticipated.
  • Impact on Marijuana Stocks: Despite its position as a leading cannabis company, Tilray admitted that it is not on track to generate positive free cash flow (FCF) this year, contrary to previous assertions. This news, along with the company's history of burning cash, contributed to the negative sentiment in the marijuana sector. The negative news from Tilray had a spillover effect on other marijuana stocks, including Cronos Group (CRON), Aurora Cannabis (ACB), and Canopy Growth (CGC). These stocks were all down as a result, with declines ranging from 3.5% to 8.5%.
25 Mar, 2024:

Canopy Growth Corporation (CGC) stock fell by 19.38% due to a spike of nearly 69% on news that Germany will begin legalizing marijuana on April 1. The initial surge was seen as an overreaction, leading to a correction in the stock price as investors reassessed the situation.

  • Germany's Legalization Impact on Canopy Growth: Germany's legalization of marijuana allows possession, home growing, and distribution by "social clubs," but commercial cultivation and retail sale are not yet permitted. This limitation may delay the immediate benefits for Canopy Growth's business, despite the unique opportunity to expand its presence in Germany's medical and recreational cannabis markets.
  • Financial Outlook and Analysts' Concerns: Canopy Growth's business remains deeply unprofitable, with a significant cash-burn rate and a substantial amount of debt. Over the past year, the company's stock has lost nearly $14 per share. Analysts warn that even with the potential market in Germany, Canopy Growth is likely to continue losing money through at least 2027. While the legalization of marijuana in Germany presents a promising opportunity for Canopy Growth, investors should approach the stock with caution. The company's financials and the timing of commercial cultivation and retail sale in Germany are key factors to consider when evaluating the long-term prospects of Canopy Growth Corporation (CGC) stock.
21 Dec, 2023:

Shares of Canopy Growth Corporation (CGC) dropped by 6.04% from $4.80 to $4.51 in the trading on Thursday, December 21, 2023. The reason why CGC down today is due to several factors:

  • Reverse Stock Split: Canopy Growth recently completed a reverse stock split, also known as a "share consolidation," where the number of outstanding shares was reduced by a factor of 10. This move was necessary to comply with Nasdaq exchange rules, as the stock had been trading below $1 per share for an extended period. Shareholders often view reverse stock splits negatively, as they can dilute the value of existing shares.
  • Market Reaction: The reverse stock split and the associated changes in share price may have generated uncertainty and unease among investors, leading to a sell-off of Canopy Growth's stock.
  • Shareholder Unfriendliness: Canopy Growth's approach to the reverse split, where fractional shares were not compensated, may have upset some investors. In typical reverse splits, investors are compensated for fractional shares, but Canopy Growth chose not to do so.
  • Business Transformation: While Canopy Growth completed the sale of its "This Works" skincare and wellness brand for approximately $12 million, investors may be cautious about the company's ongoing transformation and its ability to demonstrate sustained progress in its core North American cannabis market. In summary, Canopy Growth's stock price decline can be attributed to a combination of factors, including the reverse stock split, shareholder sentiment, and the need to show progress in its business transformation efforts.
13 Dec, 2023:

Shares of Canopy Growth Corporation (CGC) dropped by 20.45% from $0.6851 to $0.5445 in the trading on Wednesday, December 13, 2023. The reason why CGC down today is due to an announcement of a 10-for-1 reverse stock split, which is set to take effest on December 20, to maintain its Nasdaq listing. This news led to a decline in investor confidence. Investors are concerned that the reverse stock split may signal long-term challenges for CGC. The split won't issue fractional shares, which means investors owning an amount not divisible by 10 will receive fewer shares than expected.

18 Oct, 2023:

Canopy Growth Corporation (CGC) dropped by 14.04% from $0.6932 to $0.5959 in the trading on Wednesday October 18, 2023. The reason why CGC stock down today is due to congressional stagnation in weed legalization. The House of Representatives failed to elect a new Speaker on Wednesday, no business in that chamber can be advanced, including the most recent House legalization proposal, the Marijuana Opportunity Reinvestment and Expungement (MORE) Act.

18 Sep, 2023:

Canopy Growth Corporation (CGC) fell 15.56% to $1.14 after the company announced a private placement of up to $50 million to boost liquidity.

https://www.marketwatch.com/story/canopy-growths-stock-slides-10-after-it-announces-private-placement-of-up-to-50-million-to-boost-liquidity-a7274fab

$76.48
price up icon 2.07%
$114.59
price down icon 1.85%
$58.22
price up icon 0.57%
drug_manufacturers_specialty_generic RDY
$80.02
price up icon 2.43%
$11.66
price down icon 1.48%
$145.30
price down icon 0.30%
Cap:     |  Volume (24h):